Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/01/24
End: 08/01/26
Due: 08/01/27
Phase: N/A
Priority: Normal
Start: 11/01/24
End: 09/30/26
Due: 09/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer | NCT06539559 | Wang Jiayu | user2@example.com | None | 2024-08-01 | 2026-08-01 | 2027-08-01 | - | - | 2025-07-14 |
| Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer | NCT06653972 | Wang Jiayu | user2@example.com | None | 2024-11-01 | 2026-09-30 | 2027-09-30 | - | - | 2025-07-14 |